WS-2 Diabetes: Signals, Modeling and Control
Organizers
Prof. Francis J. Doyle III, Ph.D.
Harvard John A. Paulson School of Engineering and Applied Sciences
29 Oxford St.; Cambridge, MA 02138E, USA
E-mail:
Prof. Claudio Cobelli, Ph.D.
Department of Information Engineering University of Padova
Via Gradenigo 6A; 35131 Padova, Italy
E-mail:
Assistant Prof. Daniel R. Cherñavvsky ,M.D.
Center for Diabetes Technology University of Virginia
560 Ray C. Hunt Dr., 3rd Floor Charlottesville, VA 22903, USA
Abstract
Type 1 Diabetes (T1D) is an autoimmune disease leading to the destruction of the insulin-producing β- cells of the pancreas and metabolic imbalanced, characterized by the lack of capacity of the body to regulate blood glucose concentration. Therefore, patients suffering for such condition present chronic hyperglycemia that leads to a number of critical health complications including micro and macro vasculature such as limb loss, blindness and ischemic heart disease, just to cite a few. In addition periods of hypoglycemia, moderate and severe, can occur that can lead to coma, and even dead. Until now, the traditional approach for the management of diabetes, based on multiple daily subcutaneous insulin injections, has shown to be deficient in preventing short and long term complication associated with the disease. Based on the aforementioned, research efforts have been devoted in recent years to overcome the limitations of the traditional medical practice. Although the idea of a closed-loop control system (CLC), can be traced back to more than forty years ago, technological advances in the last decade such as subcutaneous continue glucose sensor (CGM) and programmable insulin pump have enable practical CLC approaches and lead to clinical validation of more efficient insulin therapies. CLC systems, also known as artificial pancreas (AP), are based on a feedback control designs for computing in real-time optimal insulin doses, based on mathematical models of diabetic metabolism.
Workshop objectives
The workshop objectives are (i) to provide to the control community a tutorial overview of the recent advances in the field of signals, modeling and control for diabetes care and (ii) to stimulate interaction
between the control community and the medical/biomedical industry community on the subject of diabetes care. In order to meet such objectives, the workshop organizers have brought together speakers taken among the most renowned leading experts in the areas of modeling and control for diabetes care. The proposed lectures will span, in a didactic way, some of the most significant aspects of the problem ranging from modeling of the diabetic patient dynamics to closed-loop control and continuous glucose monitoring sensor design. Open problems representing challenging opportunity for the control/system identification research community will also be discussed.
By bringing together leading researchers in the fields of signals, modeling and control for diabetes care, including medical industry and medical academia speakers, the organizers propose a set of tutorial lessons aimed at: (i) review the fundamental aspects and difficulties related to the problem of signal, modeling and control for blood glucose regulation in patients affected by Type 1 diabetes; (ii) provide a report on the recent advances obtained in this field highlighting the crucial role played by control theory; (iii) provide to the control community a list of challenging open problems that still need to be solved in order to realize an effective artificial pancreas systems; (iv) where the field is right now in order to bring this technology to commercialization.
Workshop structure and contents
The workshop consists of two parts. The first part encompasses a set of tutorial lectures aimed at presenting the fundamental concepts and some recent results about signal, modeling and control for diabetes care developed by leading researcher in the field of control and biomedical engineering.
The second part is explicitly devoted to show the point of view of the industrial and medical community on the subject.
The distribution of the lectures and time allocated will be as follow.
PART I: Signals, Modeling and Control for Diabetes Care: review of fundamental concepts and recent advances.
The first part consists of the 4 talks, 60 minutes each (45 minutes talk, 15 minutes discussion) listed below.
(I.1) 8:15 – 9:15 Speaker: C. Cobelli, Ph.D.- Subject: Subject: Models
Title: Minimal and Maximal Models of Glucose Metabolism: Why and How.
(I.2) 9:15 – 10.15 Speaker: Andrea Facchinetti, Ph.D.- Subject: Signals/CGMs
Title: Continuous glucose monitoring: past, present, and future
Coffee break 10:15 AM – 10:30 AM
(I.3) 10:30 – 11:30 Speaker: F. Doyle, Ph.D.; - Subject: Control
Title: Algorithms for Controlling the Artificial Pancreas
(I.4) 11:30-12:30 Speaker: B. Kovatchev, Ph.D.- Subject: AP Modular Architecture
Title: Modular Architecture of Closed-Loop Control in Diabetes: Multi-use, Multi-Signal, and Multi-Hormonal Artificial Pancreas
Lunch 12:30 PM – 1:30 PM
PART II: Signals, Modeling and Control for Diabetes Care: recent advances in the medical and industrial community.
The second part consists of the 4 talks, 60 minutes each (45 minutes talk, 15 minutes discussion), listed below.
(II.1) 1:30 – 2:30 Speaker: H. Zisser, M.D.-AP clinical trials
Title: Overview of recent AP clinical trials in T1D adult population
(II.2) 2:30 pm – 3:30 Speakers: G. Arreaza-Rubín, M.D. and A. Bremer, M.D., Ph.D –Subject: NIH- NIDDK extramural and global funds for research.
Title: NIH/NIDDK Diabetes Technology Program-Strategic perspectives (G. Arreaza-Rubín)
Title: NIH interests and directions regarding the closed-loop and extramural possibility of funds (A. Bremer)
Coffee break 3:30 PM – 3:45 PM
(II.3) 3:45-4:45 Speakers: M. Breton, Ph.D. and D. Cherñavvsky, M.D.- Subject: AP and exercise/overview of AP trials in pediatric population
Title: Auxiliary signals for the control of glycemia during and after exercise (M.Breton)
Title: Closed-Loop control for type 1 Diabetes (T1D): Overview of clinical studies in T1D pediatric population (D. Cherñavvsky)
( II.4) 4:45-5:45 Speaker: Apurv Kamath, MS.-Current state of AP commercialization
Title: Impact of Industry-Academia Collaboration in the Development and Commercialization of AP
Systems (Dexcom Perspective)
5:45-6:00 Closing Remarks: Claudio Cobelli, Ph.D. and Daniel Cherñavvsky, M.D.